Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us
  • Log out of your HL account

Alnylam Pharmaceuticals Inc (ALNY) Com Stk USD0.01

Sell:$81.78 Buy:$81.88 Change: $0.21 (0.26%)
NASDAQ:0.40%
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Sell:$81.78
Buy:$81.88
Change: $0.21 (0.26%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Sell:$81.78
Buy:$81.88
Change: $0.21 (0.26%)
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Contact details

Address:
300 3rd St
CAMBRIDGE
02142-1103
United States
Telephone:
+1 (617) 5518200
Website:
www.alnylam.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ALNY
ISIN:
US02043Q1076
Market cap:
$8.99 billion
Shares in issue:
111.21 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Bonney
    Independent Chairman of the Board
  • Barry Greene
    President
  • John Maraganore
    Chief Executive Officer, Director
  • Jeffrey Poulton
    Chief Financial Officer, Executive Vice President
  • Akshay Vaishnaw
    President - Research and Development
  • Yvonne Greenstreet
    Chief Operating Officer
  • Kelley Boucher
    Chief Human Resource Officer, Senior Vice President
  • Laurie Keating
    Executive Vice President, Chief Legal Officer, Secretary
  • Kevin Fitzgerald
    Senior Vice President, Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA, SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.